Cargando…

Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta‐analysis

Sarcopenia, which is characterized by a decrease in muscle quantity or quality, is commonly observed in patients with cancer. Recent research has reported contradictory results on the association between sarcopenia and the efficacy of immune checkpoint inhibitors (ICIs). We conducted a systematic re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takenaka, Yukinori, Oya, Ryohei, Takemoto, Norihiko, Inohara, Hidenori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517360/ https://www.ncbi.nlm.nih.gov/pubmed/34337889 http://dx.doi.org/10.1002/jcsm.12755

Ejemplares similares

Prognostic impact of sarcopenia in patients with head and neck cancer treated with surgery or radiation: A meta-analysis
por: Takenaka, Yukinori, et al.
Publicado: (2021)

Radiation vs surgery for early-stage laryngeal verrucous carcinoma: A population-based propensity score matched-study
por: Takenaka, Yukinori, et al.
Publicado: (2022)

Development and validation of a new comorbidity index for patients with head and neck squamous cell carcinoma in Japan
por: Takenaka, Yukinori, et al.
Publicado: (2017)

Small Cell Carcinoma of the Larynx Treated by Concurrent Chemoradiotherapy: A Case Report
por: Nakahara, Susumu, et al.
Publicado: (2012)

Sarcopenia’s Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Lee, Donggun, et al.
Publicado: (2021)

Performance of oral HPV DNA, oral HPV mRNA and circulating tumor HPV DNA in the detection of HPV‐related oropharyngeal cancer and cancer of unknown primary
por: Tanaka, Hidenori, et al.
Publicado: (2021)

Prognostic Impact of Sarcopenia on Clinical Outcomes in Malignancies Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Li, Shuluan, et al.
Publicado: (2021)

Transaminase Activity Predicts Survival in Patients with Head and Neck Cancer
por: Takenaka, Yukinori, et al.
Publicado: (2016)

ICU admission for solid cancer patients treated with immune checkpoint inhibitors
por: Toffart, Anne-Claire, et al.
Publicado: (2023)

Cytomegalovirus Infections in Patients Treated With Immune Checkpoint Inhibitors for Solid Malignancies
por: Anastasopoulou, Amalia, et al.
Publicado: (2023)

Metabolic tumor volume of primary tumor predicts survival better than T classification in the larynx preservation approach
por: Miyabe, Junji, et al.
Publicado: (2017)

Gram Staining for the Treatment of Peritonsillar Abscess
por: Takenaka, Yukinori, et al.
Publicado: (2012)

Sarcopenia Was a Poor Prognostic Predictor for Patients With Advanced Lung Cancer Treated With Immune Checkpoint Inhibitors
por: Li, Shuluan, et al.
Publicado: (2022)

Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis
por: Su, Qiang, et al.
Publicado: (2018)

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
por: Khaddour, Karam, et al.
Publicado: (2020)

Prognostic impact of sarcopenia on immune-related adverse events in malignancies received immune checkpoint inhibitors: a systematic review and meta-analysis
por: Li, Shuluan, et al.
Publicado: (2021)

Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy
por: Loosen, Sven H., et al.
Publicado: (2021)

Prognostic value of sarcopenia in patients with lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors
por: Lyu, Jiahua, et al.
Publicado: (2023)

Prognostic role of neutrophil–lymphocyte ratio in nasopharyngeal carcinoma: A meta-analysis
por: Takenaka, Yukinori, et al.
Publicado: (2017)

Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis
por: Zhao, Zijun, et al.
Publicado: (2022)

The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors
por: Meyers, Daniel E., et al.
Publicado: (2019)

Infectious complications of immune checkpoint inhibitors in solid organ malignancies
por: Ross, Justine Abella, et al.
Publicado: (2021)

Increasing cure rates of solid tumors by immune checkpoint inhibitors
por: Ma, Weijie, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors to Treat Malignant Lymphomas
por: Witkowska, Magdalena, et al.
Publicado: (2018)

Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NCSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study
por: Tenuta, Marta, et al.
Publicado: (2021)

Longitudinal up‐regulation of endolymphatic hydrops in patients with Meniere's disease during medical treatment
por: Fukushima, Munehisa, et al.
Publicado: (2017)

Human Papillomavirus and Cystic Node Metastasis in Oropharyngeal Cancer and Cancer of Unknown Primary Origin
por: Yasui, Toshimichi, et al.
Publicado: (2014)

Immune profile analysis of peripheral blood and tumors of lung cancer patients treated with immune checkpoint inhibitors
por: Ichiki, Yoshinobu, et al.
Publicado: (2022)

Circulating Natural Killer Cells as Prognostic Value for Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Correlation with Sarcopenia
por: Tenuta, Marta, et al.
Publicado: (2023)

Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review
por: Al-Showbaki, Laith, et al.
Publicado: (2023)

Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy
por: Sindhu, Kunal K., et al.
Publicado: (2022)

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
por: Denis, Morgane, et al.
Publicado: (2020)

Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review
por: Yang, Kaili, et al.
Publicado: (2020)

Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers
por: Yu, Yingyan
Publicado: (2021)

Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates
por: Kawashima, Shun, et al.
Publicado: (2022)

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
por: Liu, Qingxu, et al.
Publicado: (2023)

Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
por: Ahn, Ryuhjin, et al.
Publicado: (2021)

Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors
por: Melissaropoulos, Konstantinos, et al.
Publicado: (2020)

Pericardial disease in patients treated with immune checkpoint inhibitors
por: Gong, Jingyi, et al.
Publicado: (2021)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k4thp2q4hh4esgq9c2paomievl